In the European biosimilar market, Samsung Bioepis has emerged as the leader in a Soliris competitor.

Q: How long will it take to read this news story?

The story " In the European biosimilar market, Samsung Bioepis has emerged as the leader in a Soliris competitor." has 626 words across 30 sentences, which will take approximately 3 - 6 minutes for the average person to read.

Q: Which news outlet covered this story?

The story " In the European biosimilar market, Samsung Bioepis has emerged as the leader in a Soliris competitor." was covered 1 months ago by Korea Economic Daily, a news publisher based in South Korea.

Q: How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news. The outlet is headquartered in South Korea and publishes an average of 15 news stories per day. It's most recent story was published 1 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #21102305</li><li>URL: https://beamstart.com/news/samsung-bioepis-tops-in-soliris-17167985379310</li></ul>

Korea Economic Daily Logo Korea Economic Daily 1 mo ago

In the European biosimilar market, Samsung Bioepis has emerged as the leader in a Soliris competitor. - Korea Economic Daily

Quick Summary:

Considering Soliris sales stood at $805 million in Europe in 2023, its market share was estimated to have fallen to the 70 percent range since the launch of its copy drugs, while Samsung Bioepis is estimated to have reaped tens of billions of won from direct sales of Epysqli.

STOCKHOLM – Samsung Bioepis Co.'s biosimilar to Solaris for the treatment of patients with rare, life-threatening disease paroxysmal nocturnal hemoglobinuria (PNH) is gearing up to overtake the original eculizumab drug after its successful launch.

The biopharmaceutical development unit under South Korea’s Samsung Group unveiled at the 61st ERA Congress held in Stockholm between May 23 and 26 that its PNH treatment Epysqli commands the largest share of more than 50% in the Soliris biosimilar market in Europe less than one year after its launch.